IL17A and proximal spinal muscular atrophy: As an example, the upregulated TRADD and JUND were “normalized” at T10, so we may speculate that nusinersen was able to impact, e.g., the IL-17 signaling pathway in which both the genes are involved, which is in line with the potential of this therapy to mitigate the neuroinflammatory features of SMA (Nuzzo et al. 2023a).